How many drugs treat Generalized myasthenia gravis?

Drug Landscape tracks 4 marketed treatments for Generalized myasthenia gravis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/generalized-myasthenia-gravis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Generalized myasthenia gravis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Generalized myasthenia gravis (disease) competitive landscape: 4 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

4 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Generalized myasthenia gravis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ultomiris	RAVULIZUMAB	AstraZeneca	Complement Inhibitor [EPC]	Complement C5	2018-01-01
RYSTIGGO	ROZANOLIXIZUMAB-NOLI	UCB INC	Neonatal Fc Receptor Blocker [EPC]	IgG receptor FcRn large subunit p51
ULTOMIRIS	RAVULIZUMAB-CWVZ	ALEXION PHARM		Complement C5
Ultomiris	Ultomiris	Alexion Pharmaceuticals, Inc.		Complement C5

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

ALEXION PHARM · 1 drug in Generalized myasthenia gravis
Alexion Pharmaceuticals, Inc. · 1 drug in Generalized myasthenia gravis
AstraZeneca · 1 drug in Generalized myasthenia gravis
UCB INC · 1 drug in Generalized myasthenia gravis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Generalized myasthenia gravis:

Cite this brief

Drug Landscape (2026). Generalized myasthenia gravis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/generalized-myasthenia-gravis. Accessed 2026-06-10.

Generalized myasthenia gravis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing